Kalogirou E, Tosiou A, Vrachnos S, Zogopoulos V, Michalopoulos I, Tzanavari T
Genes (Basel). 2025; 16(1).
PMID: 39858584
PMC: 11764928.
DOI: 10.3390/genes16010037.
Kim B
Int J Mol Sci. 2025; 25(24.
PMID: 39769068
PMC: 11678812.
DOI: 10.3390/ijms252413299.
Mortoglou M, Lian M, Miralles F, Dart D, Uysal-Onganer P
ACS Omega. 2024; 9(48):47872-47883.
PMID: 39651070
PMC: 11618397.
DOI: 10.1021/acsomega.4c08947.
Lai C, Kwok A, Wong K
J Pers Med. 2024; 14(9).
PMID: 39338235
PMC: 11433629.
DOI: 10.3390/jpm14090981.
Han H, He T, Wu Y, He T, Zhou W
Front Cell Dev Biol. 2024; 12:1441081.
PMID: 39184916
PMC: 11341543.
DOI: 10.3389/fcell.2024.1441081.
CD24 flags anastasis in melanoma cells.
Vasileva M, Bennemann A, Zachmann K, Schon M, Frank J, Ulaganathan V
Apoptosis. 2024; 30(1-2):1-15.
PMID: 39136818
PMC: 11799124.
DOI: 10.1007/s10495-024-01990-1.
Network analysis to identify driver genes and combination drugs in brain cancer.
Roshani F, Ahvar M, Ebrahimi A
Sci Rep. 2024; 14(1):18666.
PMID: 39134610
PMC: 11319350.
DOI: 10.1038/s41598-024-69705-9.
T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells.
van Bruggen J, Peters F, Mes M, Rietveld J, Cerretani E, Cretenet G
Blood Adv. 2024; 8(17):4633-4646.
PMID: 39042920
PMC: 11401197.
DOI: 10.1182/bloodadvances.2023011934.
Unravelling the role of tumor microenvironment responsive nanobiomaterials in spatiotemporal controlled drug delivery for lung cancer therapy.
Srinivasarao D, Shah S, Famta P, Vambhurkar G, Jain N, Pindiprolu S
Drug Deliv Transl Res. 2024; 15(2):407-435.
PMID: 39037533
DOI: 10.1007/s13346-024-01673-z.
Exosomes multiplex profiling, a promising strategy for early diagnosis of laryngeal cancer.
Bocchetti M, Luce A, Iannarone C, Pasquale L, Falco M, Tammaro C
J Transl Med. 2024; 22(1):582.
PMID: 38902710
PMC: 11188179.
DOI: 10.1186/s12967-024-05396-0.
From mechanism to therapy: the journey of CD24 in cancer.
Zhao K, Wu C, Li X, Niu M, Wu D, Cui X
Front Immunol. 2024; 15:1401528.
PMID: 38881902
PMC: 11176514.
DOI: 10.3389/fimmu.2024.1401528.
LncRNA IL21-AS1 facilitates tumour progression by enhancing CD24-induced phagocytosis inhibition and tumorigenesis in ovarian cancer.
Liu J, Yan C, Xu S
Cell Death Dis. 2024; 15(5):313.
PMID: 38702326
PMC: 11068771.
DOI: 10.1038/s41419-024-06704-8.
The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS.
Grigoropoulos I, Tsioulos G, Kastrissianakis A, Shapira S, Green O, Rapti V
Respir Res. 2024; 25(1):151.
PMID: 38561798
PMC: 10983648.
DOI: 10.1186/s12931-024-02759-5.
Therapeutic and immunomodulatory potentials of mesenchymal stromal/stem cells and immune checkpoints related molecules.
Hazrati A, Malekpour K, Khorramdelazad H, Rajaei S, Hashemi S
Biomark Res. 2024; 12(1):35.
PMID: 38515166
PMC: 10958918.
DOI: 10.1186/s40364-024-00580-2.
Checkpoint CD24 function on tumor and immunotherapy.
Huang S, Zhang X, Wei Y, Xiao Y
Front Immunol. 2024; 15:1367959.
PMID: 38487533
PMC: 10937401.
DOI: 10.3389/fimmu.2024.1367959.
Surprising magic of CD24 beyond cancer.
Wang H, Shi P, Shi X, Lv Y, Xie H, Zhao H
Front Immunol. 2024; 14:1334922.
PMID: 38313430
PMC: 10834733.
DOI: 10.3389/fimmu.2023.1334922.
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.
Li X, Tian W, Jiang Z, Song Y, Leng X, Yu J
Cancer Immunol Immunother. 2024; 73(2):31.
PMID: 38279998
PMC: 10821995.
DOI: 10.1007/s00262-023-03606-0.
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H
Nat Commun. 2024; 15(1):615.
PMID: 38242888
PMC: 10798961.
DOI: 10.1038/s41467-024-44873-4.
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.
Schettini F, Palleschi M, Mannozzi F, Braso-Maristany F, Cecconetto L, Galvan P
Oncologist. 2024; 29(5):e622-e634.
PMID: 38175669
PMC: 11067809.
DOI: 10.1093/oncolo/oyad337.
Targeting CD24 as a novel immunotherapy for solid cancers.
Yang Y, Zhu G, Yang L, Yang Y
Cell Commun Signal. 2023; 21(1):312.
PMID: 37919766
PMC: 10623753.
DOI: 10.1186/s12964-023-01315-w.